Richard J. Lewis
Corporate Officer/Principal presso The University of Queensland
Posizioni attive di Richard J. Lewis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| The University of Queensland | Corporate Officer/Principal | 01/07/2009 | - |
| National Health & Medical Research Council | Corporate Officer/Principal | 01/07/2009 | - |
Storia della carriera di Richard J. Lewis
Precedenti posizioni note di Richard J. Lewis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Corporate Officer/Principal | 01/07/2009 | - |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Direttore Tecnico/Scientifico/R&S | 01/01/2000 | - |
| Fondatore | 08/02/2010 | - |
Statistiche
Distribuzione geografica
| Australia | 4 |
| Stati Uniti | 2 |
Posizioni
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Settori
| Health Technology | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Commercial Services |
| Aziende private | 2 |
|---|---|
Xenome Ltd.
Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
| National Health & Medical Research Council | Government |
- Borsa valori
- Insiders
- Richard J. Lewis
- Esperienza
